Vivani strikes reverse-merger agreement with ClearOne for BCI business

Once the transaction completes, ClearOne will be renamed as Cortigent Holdings, setting Vivani’s BCI business up with a Nasdaq listing. Once the transaction completes, ClearOne will be renamed as Cortigent Holdings, setting Vivani’s BCI business up with a Nasdaq listing. Cortigent’s products include BCI implants for vision restoration. Credit: BLACKDAY/Shutterstock.com Vivani Medical has agreed to merge its neurotech subsidiary, Cortigent, with comms equipment specialist ClearOne in a move that will create a new entity and take Vivani’s brain-computer interface (BCI) business public. Upon completion of the transaction, which is expected to close in Q3 2026, Cortigent and Nasdaq-listed ClearOne will…

Source: Medical Device Network